Browse > Article
http://dx.doi.org/10.4333/KPS.2002.32.4.321

In vitro/In vivo Correlation of Sustained Release Diltiazem  

Choi, Myoeng-Sin (Ewha Womans University)
Kang, Chan-Soon (Department of Drug Evaluation, Korea Food and Drug Administration)
Choi, Bo-Kyung (Department of Drug Evaluation, Korea Food and Drug Administration)
Hong, Chong-Hui (Chungnam National University)
Kim, Kil-Soo (Ewha Womans University)
Publication Information
Journal of Pharmaceutical Investigation / v.32, no.4, 2002 , pp. 321-325 More about this Journal
Abstract
IVIVC (In vitro/in vivo correlation) is useful for predicting in vivo results from in vitro data. The aim of this study was to develop IVIVC of sustained release diltiazem. For this purpose, three types of diltiazem tablets with different in vitro dissolution rates were prepared. An in vitro dissolution testing method comprising of paddle apparatus, 50 rpm, water as dissolution medium was developed. Under these condition, we demonstrated that AUCinf could be predicted by evaluating $d_{70%}$ (time dissolved 70%) in vitro since the in vivo AUCinf was correlated with the in vitro $d_{70%}$ (r=-0.9981).
Keywords
Diltiazem; Dissolution test; In vivo-in vitro correlation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ph. Herman, S. D. Rodger, G. Remones, J. P. Thenot, D. R. London, P. L. Morselli, Pharmacokinetics of diltiazem after intravenous and oral administration. Eur. J. Clin. Pharmacol., 24, 349-352 (1983)   DOI   ScienceOn
2 B. Sreenivasa Rao, A. seshasayana, S. V. Pardha saradhi, N. Ravi Kumar, Cheruvu P. S. narayan, K. V. Ramana Murthy, Correlation of in vitro release and in vivo absorption characteristics of rifampicin from ethylcellulose coated nonpareil beads, Int. J. Pharma., 230, 1-9 (2001)   DOI   ScienceOn
3 FDA Guidance for industry: modified release solid oral dosage forms; scale-up and post approval changes (SUPAC-MR); chemistry, manufacturing and controls; in vitro dissolution testing and in vivo bioequivalence documentation, september, 1997a
4 FDA Guidance for industry: Extended release oral dosage forms; development, evaluation and application of in vitro/in vivo correlation, september, 1997b
5 Aristides Dokoumetzidis and Panos Macheras, A population growth models of dissolution, Pharm. Res., 14(9), 1122-1126 (1997)   DOI   ScienceOn
6 M. Zahirul I. Khan, Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data : challenges and opportunities, Int. J. Pharm., 140, 131-143 (1996)   DOI   ScienceOn
7 Venkata ramana S. Uppoor M. Pharm., Ph. D., R. Ph., Regularoty perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations, J. Controlled release, 72, 127-132 (2001)   DOI   ScienceOn
8 Skelley, J. P., Amidon, G. L., Barr, W. J., Benet, L. Z., Carter, J. E., Robinson, J. R., Shah, V. P., Yacobi, A., Report of the workshop on in-vitro in-vivo testing and correlation for oral controlled modified-release dosage forms. J. Pharm. Sci., 79, 849-854 (1990)   DOI
9 Robert E. Wiens, Dennis J. Runser, Joseph P. Lacz, and Dan C. Dimmitt, Quantitation of diltiazem and desacetyldiltiazem in dog plasma by high-performance liquid chromatography, J. Pharm. Sci., 73(5), 688-689 (1984)   DOI
10 Nattee Sirisuth and Natalie D. Eddington, In-vitro-in vivo correlation definitions and regulatory guidance, Int. J. Generic drugs, ISSN 0793 758X US/canada
11 FDA Guidance for industry: Dissolution testing of immediate release solid oral dosage forms, August, 1997c
12 Nattee sirisuth and Natalie D. Eddington, Vitro-in vivo correlations, Int. J. Generic drugs, 250-258, ISSN 0793 694X-US/Canada
13 Gordon L. Amidon, Hans Lennernas, Vinod P. Shah, and John R. Crison, A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12(3), 413-420 (1995)   DOI   ScienceOn
14 FDA Guidance for industry: Immediate release solid dosage forms; scale-up and post approval changes (SUPAC-IR); chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation, November, 1995
15 Vinod P. Shah, Yi Tsong, Pradeep Sathe, and Jea-Pei Liu, in vitro dissolution profile comparison-statistics and analysis of the similarity factor,$f_2$ , Pharm. Res., 15(6), 1998
16 Bee-Hwan Chung and Chang-Koo Shim, Dissolution of theophylline from sustained-release dosage forms and correlation with saliva bioavailability parameters, J. Pharm. Sci., 76(10), 784-787 (1987)   DOI
17 P. Costa, An alternative method to the evaluation of similarity factor in dissolution testing, Int. J. Pharm., 220, 77-83 (2001)   DOI   ScienceOn
18 G. Bianchetti, M. Regazzi, M. Rondanelli, V. Ascalone, M. Morselli, Bioavailability of diltiazem as a function of the administered dose., Biopharm. Drug Disp., 12, 391-401 (1991)   DOI   ScienceOn
19 E. U. Kolle, H. R. Ochs, K. O. Vollmer, Pharmacokinetic model of diltiazem. Arzneim. Forsch./Drug Res., 33, 972-977 (1983)